BRAF-Mutant Papillary Thyroid Cancer

1. Disease Information

Overview

BRAF-mutant papillary thyroid cancer is a molecular subtype of papillary thyroid carcinoma (PTC) defined by the presence of activating mutations in the BRAF serine/threonine kinase gene, most commonly the V600E hotspot mutation. PTC itself accounts for 85–90% of all thyroid malignancies, making it the most common endocrine cancer worldwide (PMID: 40980146). The BRAF V600E mutation occurs as a somatic (acquired) event in thyroid follicular cells and results in constitutive activation of the MAPK signaling pathway independent of upstream receptor tyrosine kinase stimulation.

Key Identifiers

Synonyms and Alternative Names

• BRAF V600E-positive papillary thyroid carcinoma
• BRAF-like PTC (TCGA molecular classification)
• BRAF-mutated differentiated thyroid cancer (DTC)
• Papillary thyroid cancer, classic variant (most commonly BRAF V600E-driven)
• PTC with BRAF V600E mutation

Information Sources

This characterization integrates aggregated disease-level resources (TCGA, COSMIC, GBD, SEER) with findings from individual patient cohorts, clinical trials, meta-analyses, and single-cell transcriptomic studies. The evidence base spans human clinical data, model organism studies, in vitro experiments, and computational analyses.

2. Etiology

Disease Causal Factors

The primary causal event in BRAF-mutant PTC is the somatic acquisition of the BRAF V600E mutation (chr7:140453136 A>T, GRCh37) in thyroid follicular epithelial cells. This missense mutation substitutes valine with glutamic acid at position 600 in the activation segment of the BRAF kinase domain, mimicking phosphorylation and locking the kinase in a constitutively active conformation. This results in continuous signaling through the RAS-RAF-MEK-ERK pathway, driving uncontrolled cell proliferation and survival (PMID: 39961465).

The BRAF V600E mutation is classified as a Class I BRAF mutation—a point mutation that activates BRAF as a monomer, independent of RAS signaling or dimerization (PMID: 39961465). This distinguishes it from Class II (in-frame insertions/deletions) and Class III (gene fusions) BRAF alterations.

Risk Factors

Genetic Risk Factors:

• BRAF V600E somatic mutation: The defining oncogenic driver, present in 40–80% of PTC across studies. A 2025 single-institution study found 78.7% of 301 PTC patients harbored BRAF V600E (PMID: 40237893). Among TCGA PTC samples, 48.4% (240/496) had BRAF mutations, with V600E comprising 97.9% (235/240).
• GWAS susceptibility loci: Multiple genome-wide association studies have identified DTC risk loci that may modify BRAF-mutant PTC susceptibility:
• 9q22.33 (FOXE1): rs965513, OR=1.7 per A allele (95% CI 1.2–2.3) (PMID: 25879635)
• 14q13.3 (NKX2-1): rs944289, OR=1.6 per A allele (95% CI 1.2–2.1) (PMID: 25879635)
• 2q35 (DIRC3): Confirmed across multiple populations (PMID: 23894154)
• 8p12 (NRG1): rs6996585, P=1.08×10⁻⁸ in Korean GWAS (PMID: 28703219)
• BATF and DHX35: rs10136427 (OR=1.30) and rs7267944 (OR=1.32) in Italian populations (PMID: 25029422)
• TERT promoter co-mutation: Synergistically worsens prognosis (see Section 4)

Environmental Risk Factors:

• Ionizing radiation exposure: The most well-established environmental risk factor for DTC. A study of indigenous populations near the former Semipalatinsk Nuclear Test Site found BRAF V600E exclusively in papillary carcinoma samples among radiation-exposed individuals (PMID: 41370693).
• Iodine intake: Dose-response meta-analysis of 25 studies (54,621 participants) revealed a U-shaped nonlinear relationship between urinary iodine concentration and thyroid nodule risk (P for nonlinearity <0.001), with increased risks at both deficient and excessive iodine levels (PMID: 41675569).
• Volcanic area residence: Exposure to volcanic emissions (gas, ash, lava) contaminates food chains with toxic compounds (PMID: 30104523).
• Obesity/metabolic dysfunction: NAFLD (non-alcoholic fatty liver disease) is an independent risk factor for lymph node metastasis in PTC (OR=1.285, 95% CI 1.052–1.570) and is associated with higher incidence of BRAF V600E mutation (PMID: 36696026).
• Sex: Female predominance (2–4:1 female-to-male ratio), with women accounting for 67% of all thyroid cancer cases globally (PMID: 41726144).
• Age: Mean age at diagnosis 40–45 years for PTC (PMID: 23014067).

Protective Factors

• Adequate iodine intake: More-than-adequate iodine showed a trend toward lower thyroid nodule prevalence (PMID: 41675569).
• Iodine prophylaxis legislation: Adoption of iodine prophylaxis programs improved thyroid cancer epidemiological outcomes in subsequent generations (PMID: 41370693).

Gene–Environment Interactions

The shift in PTC oncogenic patterns over recent decades—from RET/PTC rearrangements to BRAF V600E dominance—suggests changing environmental exposures interact with genetic susceptibility. Radiation exposure correlates with RET/PTC rearrangements, while the increasing BRAF V600E prevalence may reflect different environmental carcinogens or detection biases (PMID: 23014067).

3. Phenotypes

Clinical Presentation

BRAF V600E-specific associations (PMID: 40237893): - Classic PTC morphology: 88% of classic subtype PTCs express BRAF V600E - Tall cell variant: 100% express BRAF V600E (most aggressive histological subtype) - Follicular variant: Only 38% express BRAF V600E - Association with infiltrative borders, extrathyroidal extension, and intraglandular tumor spread (PMID: 26271724)

Quality of Life Impact

HRQOL meta-analysis of PTMC treatments found uncomplicated QALY weights ranging from 0.975 to 0.992, with no significant difference between active surveillance, thermal ablation, and surgery (P=.15) (PMID: 41452620). Patient treatment preferences are driven by aversion to treatment complications rather than to the treatments themselves (PMID: 41006152). Post-thyroidectomy patients report challenges in sensory function, body satisfaction, eating, speaking, and social interactions (PMID: 38384638). Thyroid cancer survivors report significant unmet informational, psychological, emotional, and practical support needs, often influenced by the "good cancer" label (PMID: 40402541).

4. Genetic/Molecular Information

Causal Gene: BRAF

Pathogenic Variants

BRAF V600E (c.1799T>A, p.Val600Glu): - Variant type: Missense (Class I BRAF mutation) - Somatic origin: Acquired in thyroid follicular cells; not inherited - Frequency in PTC: 40–80% across studies; TCGA: 48.4% (240/496 samples) - Functional consequence: Gain-of-function; constitutive kinase activation (~500-fold increased activity) - ACMG classification: Pathogenic (somatic oncogenic variant) - Population frequency: Extremely rare as germline variant in gnomAD; functionally exclusive to somatic tumors

Rare non-V600E BRAF variants in PTC (TCGA data): - K601E (n=1), N581_A598dup (n=1), K591_A598dup (n=1), P490_Q494del (n=1), T488_P492del (n=1) - Mutation types: 236 missense, 2 in-frame insertions, 2 in-frame deletions

Co-occurring Mutations and Modifier Genes

TERT promoter mutations (C228T, C250T): - Found in 38.2% of DTC patients harboring BRAF V600E (PMID: 40988283) - Coexisting BRAF V600E + TERT independently elevates risk of loss of RAI avidity (OR=4.8, P=.009) and accelerates recurrence (PMID: 40988283) - TERT is an independent predictor of lateral lymph node metastasis (OR=2.272, 95% CI 1.078–4.786) (PMID: 40184730)

TP53 mutations: Observed in the ATC component during dedifferentiation from PTC; not typically found in well-differentiated PTC (PMID: 40887557)

Additional co-occurring alterations: DICER1 (7%), PTEN (6%), RET (4%) in multifocal PTC (PMID: 40235071)

Epigenetic Information

• Promoter methylation: BRAF V600E correlates with methylation of TIMP3, CDH13, RASSF1A, and RARB tumor suppressor genes (PMID: 31006665)
• miRNA dysregulation: miR-146b, miR-221/222, and miR-375 are upregulated in BRAF V600E PTC and associated with aggressive behavior (PMID: 41660935)
• NOX4-mediated epigenetic mechanism: NOX4-derived oxidative DNA damage impairs thyroid differentiation through epigenetic reprogramming in BRAF-mutated RAI-refractory cells (PMID: 41694580)
• Global hypomethylation: Associated with chromosomal instability in aggressive PTC (PMID: 41660935)

5. Environmental Information

Environmental Factors

• Ionizing radiation: Most established risk factor; includes external radiation exposure, nuclear fallout, and therapeutic radiation (PMID: 41370693; PMID: 23132514)
• Volcanic emissions: Toxic compounds in gas, ash, and lava contaminate ground water and food chains (PMID: 30104523)
• Xenobiotic compounds: Environmental pollutants (PCBs, nitrates) accumulate and exert carcinogenic effects (PMID: 30104523)

Lifestyle Factors

• Obesity: BMI associated with altered clinicopathological features; MAFLD/NAFLD associated with higher BRAF V600E incidence and lymph node metastasis (PMID: 36696026; PMID: 38787506)
• Iodine intake: Both deficiency and excess modify thyroid cancer risk in a U-shaped relationship (PMID: 41675569)

Infectious Agents

Not directly applicable. No established infectious etiology for BRAF-mutant PTC, though chronic lymphocytic thyroiditis (Hashimoto's) shows complex immunological relationships with PTC (PMID: 38940753).

6. Mechanism / Pathophysiology

Molecular Pathways

Primary pathway — MAPK/ERK cascade:

BRAF V600E (constitutively active)
    |
    v
MEK1/2 phosphorylation (constitutive)
    |
    v
ERK1/2 phosphorylation (constitutive)
    |
    |---> Cell proliferation (Cyclin D1, c-Myc)
    |---> Survival (BCL-2 family)
    |---> NIS suppression --> RAI refractoriness
    |---> Dedifferentiation gene silencing
    |---> PD-L1 upregulation --> Immune evasion
    +---> Tumor invasion/migration (MMP, EMT)

The BRAF V600E mutation "activates the MAPK pathway and suppresses genes involved in iodine metabolism and differentiation" (PMID: 41368991). This constitutive signaling operates independently of extracellular growth factor stimulation.

Secondary pathway involvement: - PI3K/AKT/mTOR: Dysregulated in concert with MAPK; contributes to resistance (PMID: 39961465) - WNT/beta-Catenin: Beta-catenin attenuation inhibits tumor growth and promotes differentiation in BRAF-mutant models (PMID: 34224366) - NF-kB signaling: Drives organoid maturation; inhibition synergistically enhances therapeutic efficacy (PMID: 41761289)

Cellular Processes

• NIS suppression and RAI refractoriness: Up to 60% of PTC harbor BRAF V600E and may become RAI-refractory. NOX4-derived oxidative DNA damage impairs thyroid differentiation through an epigenetic mechanism, silencing NIS expression (PMID: 41694580). GO: GO:0006882 (cellular zinc ion homeostasis); GO:0055085 (transmembrane transport)
• Immune evasion: BRAF V600E positively correlates with PD-L1 and PD-1 expression in PTC tumor microenvironment (Type 1 PD-L1+/PD-1+ in 41% of cases), suggesting immune checkpoint therapies may be effective (PMID: 29651624)
• Dedifferentiation cascade: Progressive accumulation of TERT, TP53 mutations drives transition from PTC to PDTC to ATC, with LINE-1 retrotransposons and endogenous retroviruses reactivated during this process (PMID: 41462994; PMID: 41296188)
• Metabolic reprogramming: Fatty acid oxidation drives acetyl-CoA-dependent H3K9ac epigenetic reprogramming to promote adaptive resistance to BRAF-targeted therapy (PMID: 41862440)

Protein Dysfunction

BRAF V600E results in a constitutively active kinase domain (gain-of-function). The glutamic acid substitution at position 600 mimics the phosphorylated state of the activation segment, resulting in approximately 500-fold increased basal kinase activity. This removes the requirement for upstream RAS activation and RAF dimerization for signaling (PMID: 39577552).

Resistance Mechanisms

Three major resistance pathways to BRAF inhibitors have been identified:

1. TAZ/Hippo pathway: CRISPR screens identified TAZ (WWTR1) deficiency as synthetically lethal with BRAF inhibitor in ATC; TAZ loss triggers ferroptosis (PMID: 42035477)
2. Fatty acid oxidation (FAO): FAO drives acetyl-CoA-dependent H3K9ac epigenetic reprogramming mediating adaptive resistance (PMID: 41862440)
3. RAS pathway feedback activation: BRAF inhibitors induce feedback activation of RAS signaling in thyroid cancer cells (PMID: 34072194)

Molecular Profiling

Transcriptomics (TCGA): - BRAF-like vs. RAS-like molecular classification based on gene expression profiles - BRAF-like tumors characterized by MAPK pathway activation signature - Transcriptomic classifiers ("BRAF-like" and "RAS-like") more accurately predict iodine avidity, tumor aggressiveness, and treatment response than histology or genotype alone (PMID: 41685247)

Single-cell RNA sequencing: - scRNA-seq reveals "differentiation-dependent trajectory of tumor immune microenvironment remodeling—from immune activation/suppression coexistence in PTC, to immune exclusion in PDTC, and terminal exhaustion in ATC" (PMID: 41562080) - RGS5+ tumor subpopulation identified with prognostic significance; high prognostic immune score linked to genetic instability (PMID: 40132388) - Intra-tumoral heterogeneity in BRAF V600E PTC includes differentiation-dependent functional states (PMID: 41935217)

Proteomics: - Differential activation of MAPK and PI3K pathways critical for enhancing lateral lymph node metastatic potential (PMID: 39600146) - Patient-derived organoids (DEOs) achieve 92% driver gene concordance with parental tumors and faithfully recapitulate histopathological architecture and immune microenvironment (PMID: 41761289)

7. Anatomical Structures Affected

Organ Level

Tissue and Cell Level

• Thyroid follicular epithelial cells (CL:0002258): Primary cell of origin for BRAF-mutant PTC
• Thyroid follicular tissue: Papillary architecture with fibrovascular cores, psammoma bodies
• Tumor microenvironment: CD3+, CD56+, CD68+, alpha-SMA+ cells recapitulated in patient-derived organoids (PMID: 41761289)

Subcellular Level

• Cytoplasm/cytosol (GO:0005829): BRAF kinase signaling
• Cell membrane (GO:0005886): NIS (SLC5A5) expression loss
• Nucleus (GO:0005634): ERK-mediated transcriptional changes
• Endoplasmic reticulum (GO:0005783): Unfolded protein response under BRAF inhibitor treatment (PMID: 42035477)

Localization

Thyroid nodules demonstrate right-side predominance (P=0.0004), and right-sided PTC with lymph node metastasis shows significantly more right-side-affected LNM (P=0.0007) (PMID: 40050757). The tumor can be unilateral or bilateral, unifocal or multifocal.

8. Temporal Development

Onset

• Typical age of onset: Adults aged 40–45 years for PTC (PMID: 23014067); median age 56 years for tall cell variant (PMID: 23682579)
• Pediatric PTC: BRAF V600E found in 50.8% of pediatric PTC (Chinese cohort, n=124); independently predicts non-excellent ATA outcomes (aOR=3.45, 95% CI 1.37–8.70) (PMID: 41499172; PMID: 39982551)
• Onset pattern: Insidious; typically discovered incidentally on imaging or as palpable thyroid nodule

Progression

AJCC 8th Edition Staging (age-dependent for DTC): - Stage I: Age <55 with any T, any N, M0; or age >=55 with T1-T2, N0, M0 - Stage II: Age <55 with any T, any N, M1; or age >=55 with T1-T2, N1, M0 or T3, N0-N1, M0 - Stage III-IV: Age >=55 with advanced T-stage, extensive nodal disease, or distant metastases

Disease course: Most patients (79.1%) present with early-stage disease. The 2022 WHO classification introduced "differentiated high-grade thyroid carcinoma" (DHGTC) as an intermediate entity between well-differentiated PTC and ATC (PMID: 36193717).

Dedifferentiation pathway (PMID: 41462994):

Well-differentiated PTC (BRAF V600E)
    | + TERT promoter mutation
    v
Poorly differentiated TC (PDTC)
    | + TP53 mutation
    v
Anaplastic thyroid carcinoma (ATC)

Recurrence patterns: Most recurrences occur within the first year (23.3%) or after 10 years post-thyroidectomy (35.7%). Patients with very early recurrences (<6 months) had TERT/BRAF V600E mutations in 69% of cases (PMID: 37336036).

9. Inheritance and Population

Epidemiology

• Global thyroid cancer incidence: Age-standardized incidence rate increased from 2.06 to 2.91 per 100,000 (1990–2021), EAPC=1.25 (PMID: 41726144)
• Global mortality: Modest decline (EAPC=-0.23), but DALYs remained high (14.57 million in 2021) (PMID: 41726144)
• Overdiagnosis: Estimated at approximately 25% globally; population-based study across 63 countries found 75.6% of 2.3 million thyroid cancer cases attributable to overdiagnosis (PMID: 39389067; PMID: 39330046)

Genetic Inheritance

BRAF V600E in PTC is a somatic mutation (not inherited). However: - Multifactorial/polygenic susceptibility: GWAS loci (FOXE1, NKX2-1, DIRC3, NRG1, BATF) confer inherited susceptibility to DTC - Familial non-medullary thyroid carcinoma: ~5% of PTC cases show familial clustering; modifier genes influence susceptibility - No Mendelian inheritance pattern for BRAF-mutant PTC specifically

Population Demographics

• Sex ratio: Female-to-male ~2.5–4:1; women account for 67% of cases globally (PMID: 41726144)
• Geographic variation: Highest incidence in South Korea, Cyprus, Ecuador, China, and Turkiye; high-SDI regions account for 72% of cases due to intensive screening, while low-SDI regions contribute 68% of deaths due to delayed diagnosis (PMID: 41726144; PMID: 39389067)
• BRAF V600E prevalence varies geographically: From 40% to >78% depending on population and study design

10. Diagnostics

Clinical Tests

Imaging: - Thyroid ultrasound (primary modality): ACR TI-RADS risk stratification system for thyroid nodules (PMID: 33112199) - CT neck with contrast: Optional for baseline AS assessment; evaluates extrathyroidal extension - I-123/I-131 whole-body scan: Assesses RAI avidity post-thyroidectomy - F-18-FDG PET/CT: For RAI-refractory disease and ATC

Laboratory tests: - Serum thyroglobulin (Tg): Primary tumor marker; ATA 2025 raised excellent-response threshold to 2.5 ng/mL (PMID: 41697551) - Anti-thyroglobulin antibodies (TgAb) - TSH, free T4

Biopsy: - Fine-needle aspiration biopsy (FNAB) with Bethesda System cytological classification - BRAF V600E immunohistochemistry (VE1 antibody): 88% concordance with NGS (PMID: 40614342)

Genetic/Molecular Testing

• BRAF V600E testing: Single-gene PCR, pyrosequencing, or allele-specific PCR from FNA or surgical specimens
• NGS panels: Myriapod panel (16 genes), Archer DX VariantPlex (31 genes) + FusionPlex (40 genes) achieve 100% sensitivity, 95.5% specificity (PMID: 41370117)
• 4-gene NGS panel (BRAF + 3 others): Cost-effective for predicting PTC in indeterminate cytology (PMID: 42083301)
• Liquid biopsy: ctDNA detection of BRAF V600E in plasma feasible; detected in 79.7% of malignant cases using 8-gene panel (PMID: 36744987)
• Transcriptomic classifiers: Thyroid GuidePx and similar tools classify tumors as "BRAF-like" vs "RAS-like" (PMID: 41685247)

Clinical Criteria

• ATA 2015 / ATA 2025 risk stratification: Low, intermediate, and high-risk categories based on clinicopathological features
• ATA 2025 update: Reclassified 89.1% of low-risk DTC as excellent response at baseline vs. 49.2% under ATA 2015 (P<0.001) (PMID: 41697551)

Differential Diagnosis

11. Outcome/Prognosis

Survival and Mortality

Prognostic Factors

Adverse prognostic factors: - BRAF V600E + TERT co-mutation (OR for RAI refractoriness = 4.8) - Age >=55 years with extrathyroidal extension (26.47-fold higher odds of incomplete response) (PMID: 41275349) - Tall cell variant histology (92.6% BRAF V600E positive; 36% present at stage III/IVA) (PMID: 23682579) - Hobnail variant (75% BRAF and p53 positivity) (PMID: 40560352) - Distant metastasis, incomplete resection, male sex, non-papillary histology

Favorable prognostic factors: - Young age at diagnosis (<55 years) - Classic PTC without high-grade features - Absence of TERT co-mutation - RAS-mutant or DICER1-mutant molecular profile (in pediatric PTC) (PMID: 41499172)

Prognostic Biomarkers

• BRAF V600E + TERT promoter co-mutation: Strongest molecular predictor of aggressive behavior
• Serum VEGFA: Elevated baseline independently associated with poor PFS (PMID: 31558473)
• RGS5+ tumor subpopulation: Outperforms existing models in predicting patient outcomes (PMID: 40132388)
• miR-146b, miR-221, miR-375: Promising predictors of aggressive disease progression (PMID: 41660935)

12. Treatment

Surgical Treatment (MAXO:0000136 — Thyroidectomy)

Radioactive Iodine Therapy (MAXO:0001298)

• Selective use recommended based on risk stratification
• RAI not significantly associated with DSS overall, but associated with >80% risk reduction in metastatic DTC (HR 0.192; CI 0.088–0.417) (PMID: 41817109)
• Decreasing utilization: adjuvant RAI rates fell from 48.7% to 19.3% after 2015 guidelines (PMID: 36326739)

Targeted Therapy (MAXO:0001525 — Targeted molecular therapy)

BRAF/MEK Inhibitor Redifferentiation:

Dabrafenib (150 mg BID) + trametinib (2 mg daily) for RAI-refractory BRAF V600E DTC: - Phase II trial (n=24): Restored abnormal I-131 uptake from 5% at baseline to 95% on post-therapy scan - At 6 months: PR 38%, SD 52%, PD 10% - 12-month PFS 82%, 24-month PFS 68% (PMID: 37074727)

Multikinase Inhibitors for RAI-Refractory DTC:

Real-world lenvatinib data: median PFS 36.0 months, OS 76.7 months, ORR 52.3%, DCR 95.5% (PMID: 41565294).

Immunotherapy

• BRAF V600E ATC: Kinase inhibitors + anti-PD-1 achieved mOS not reached for BRAF V600E ATC vs. 4.0 months for non-BRAF (P=0.049); ORR 61.1% (PMID: 39395384)
• Neoadjuvant mutation-based therapy: Converted 9/12 unresectable ATC to resectable (PMID: 40927298)
• PD-L1/PD-1 correlation: BRAF V600E positively correlates with PD-L1 expression, suggesting potential immunotherapy targets (PMID: 29651624)

Active Surveillance (MAXO:0000950)

For low-risk PTMC (Bethesda V–VI, <=1 cm, no adverse features): - Initiated 1993 at Kuma Hospital; zero thyroid-cancer-related deaths reported in 30+ years (PMID: 41196684) - Argentine cohort (n=104): 5- and 10-year cumulative tumor growth 7% and 8%; LN metastasis 0.9% (PMID: 40425952) - 2025 Korean guideline: Recommends AS for adults with confirmed PTMC without adverse features (PMID: 40598902) - HRQOL: No significant difference between AS, ablation, and surgery for uncomplicated PTMC (P=.15) (PMID: 41452620)

Experimental Therapies

• Triple therapy (BRAF + MEK + AKT): Phase I study showed tolerability and objective responses (PMID: 38261444)
• Disulfiram metabolite Cu(DDC)2: Enhances NIS function via proteostasis modulation for RAI therapy (PMID: 41679192)
• Reverse transcriptase inhibitors: Suppress retroelement activity and may restore RAI uptake (PMID: 41296188)
• Patient-derived organoids: Microfluidic DEOs with 76% success rate enable personalized drug screening (PMID: 41761289)

13. Prevention

Primary Prevention

• Radiation protection: Minimize unnecessary radiation exposure; iodine prophylaxis for nuclear emergencies
• Iodine supplementation: Maintain adequate iodine intake to prevent both deficiency and excess-related risk
• Obesity management: Address metabolic risk factors (MAFLD/NAFLD)

Secondary Prevention (Screening and Early Detection)

• Avoiding overdiagnosis: Global thyroid cancer overdiagnosis estimated at ~25%; "incidence has risen exponentially, mostly driven by overdiagnosis of low-risk tumors; however, a small rise in incidence of higher risk tumors has been noted" (PMID: 39087407)
• ACR TI-RADS: Ultrasound-based risk stratification reduces unnecessary biopsies by 19.9–46.5% compared to other systems (PMID: 33112199)
• Molecular testing of indeterminate nodules: BRAF V600E testing on FNA reduces unnecessary surgery

Tertiary Prevention

• Dynamic risk stratification: ATA 2025 response assessment categories (excellent, indeterminate, biochemical incomplete, structural incomplete)
• Active surveillance protocols: Follow-up ultrasound every 6 months for 2 years, then annually (PMID: 40598902)
• TSH suppression: Tailored to risk category
• Genetic counseling: For familial non-medullary thyroid cancer families

14. Other Species / Natural Disease

Comparative Biology

• BRAF ortholog: BRAF is highly conserved across vertebrates
• Mouse (Mus musculus): NCBI Gene ID 109880
• Zebrafish (Danio rerio): NCBI Gene ID 403065

• Dog (Canis lupus familiaris): NCBI Gene ID 475526

• Canine thyroid carcinoma: Dogs develop follicular thyroid carcinoma naturally, though BRAF V600E is not a prominent driver in canine thyroid tumors. Canine thyroid cancer shares some histopathological features with human DTC.

• Evolutionary conservation: The MAPK/ERK signaling pathway is evolutionarily conserved from invertebrates to humans, with BRAF orthologs present in Drosophila (dRaf) and C. elegans (lin-45). Mutations in these orthologs produce developmental phenotypes relevant to understanding BRAF oncogenesis.

Zoonotic Potential

Not applicable — BRAF-mutant PTC is not an infectious or transmissible disease.

15. Model Organisms

Mouse Models

• BrafV600E knock-in mice (thyroid-specific): Thyroid-targeted expression of BrafV600E using Tg-Cre or TPO-Cre drivers produces autochthonous PTC that recapitulates human disease features, including papillary architecture and loss of differentiation markers. scRNA-seq analysis of these models reveals transcriptional heterogeneity and hierarchical trajectories of malignant thyrocytes (PMID: 41935217).
• Beta-catenin attenuation studies: Demonstrated that WNT pathway inhibition can promote differentiation in BRAF-mutant thyroid tumors (PMID: 34224366)
• Limitations: Mouse models may not fully recapitulate human immune microenvironment or dedifferentiation dynamics

Cell Lines

• BCPAP: Human PTC cell line harboring BRAF V600E; widely used for signaling and drug sensitivity studies
• 8505C: ATC cell line with BRAF V600E; used for resistance mechanism studies
• KTC-1: PTC cell line for BRAF inhibitor studies
• Patient-derived organoids (PDOs/DEOs): Microfluidic-generated organoids achieve 92% driver gene concordance, recapitulate immune microenvironment (CD3+/CD56+/CD68+/alpha-SMA+), and enable personalized drug screening (PMID: 41761289)

Zebrafish Models

Zebrafish expressing human BRAF V600E develop thyroid hyperplasia, useful for high-throughput drug screening and studying early oncogenic events.

Key Findings — Statistical Evidence Summary

Finding 1: BRAF V600E Prevalence and Prognostic Impact

BRAF V600E is the most common oncogenic driver in PTC (40–80% prevalence). Meta-analysis of 46 studies (20,570 patients) confirmed significant association with lymph node metastasis (OR=1.38, 95% CI 1.17–1.61) and borderline recurrence risk (OR=1.56, 95% CI 1.00–2.41) (PMID: 41419184). A 2025 study found 78.7% prevalence, with subtype-specific distribution: 88% classic, 38% follicular variant, 100% tall cell (PMID: 40237893).

Finding 2: MAPK Activation and NIS Suppression

BRAF V600E constitutively activates the MAPK pathway and suppresses iodine metabolism genes (PMID: 41368991). NOX4-derived oxidative DNA damage impairs differentiation via epigenetic mechanisms (PMID: 41694580).

Finding 3: BRAF + TERT Synergy

Coexisting mutations independently elevated RAI refractoriness risk (OR=4.8, P=.009) (PMID: 40988283). TERT alone predicts lateral LN metastasis (OR=2.272) (PMID: 40184730).

Finding 4: Redifferentiation Therapy Success

Dabrafenib-trametinib restored RAI uptake from 5% to 95% in BRAF V600E RAI-refractory DTC, with PR in 38% and 24-month PFS of 68% (PMID: 37074727).

Finding 5: Resistance Mechanisms

Three validated mechanisms: TAZ/Hippo (ferroptosis) (PMID: 42035477), FAO-driven epigenetic reprogramming (PMID: 41862440), and RAS feedback activation (PMID: 34072194).

Finding 6: Active Surveillance Safety

Over 30 years of AS data with zero thyroid-cancer-related deaths (PMID: 41196684). MAeSTro study (n=1,177) and multiple international cohorts validate this approach (PMID: 39962344).

Finding 7: Immunotherapy in BRAF-Mutant ATC

Kinase inhibitors + anti-PD-1 achieved ORR 61.1% and mOS not reached in BRAF V600E ATC vs. 4.0 months for non-BRAF (P=0.049) (PMID: 39395384).

Finding 8: Global Overdiagnosis

Estimated at ~25% of thyroid cancers globally, driven by screening intensity in high-SDI regions (PMID: 39389067; PMID: 39330046).

Mechanistic Model: From Mutation to Clinical Phenotype

+----------------------------------------------------------------+
|                    INITIATING EVENT                             |
|         Somatic BRAF V600E mutation (c.1799T>A)                |
|              in thyroid follicular cell                          |
+----------------------------+-----------------------------------+
             |
             v
+----------------------------------------------------------------+
|              CONSTITUTIVE MAPK ACTIVATION                       |
|    BRAF V600E --> MEK1/2 --> ERK1/2 (independent of RAS)       |
+------+----------+----------+----------+----------+-------------+
       |          |          |          |          |
       v          v          v          v          v
  Proliferation  NIS loss   PD-L1 up  TSG silenc  EMT/Invasion
  (Cyclin D1)   (RAI-R)   (immune    (RASSF1A,   (MMP, TGFb)
           evasion)   TIMP3 meth)
       |          |          |          |          |
       +----------+----------+----------+----------+
             |
  +------------------+------------------+
  v                  v                  v
    Low-risk PTC    Intermediate PTC    High-risk PTC
    (indolent)      (moderate risk)     (aggressive)
  |                  |                  |
  |         + TERT mutation              |
  |                  |                  v
  |                  v             Dedifferentiation
  |          RAI-refractory        + TP53 mutation
  |           disease                   |
  |                  |                  v
  |                  |              ATC (lethal)
  v                  v                  v
    Active            BRAF/MEK inhibitor   Immunotherapy +
    surveillance      redifferentiation    targeted therapy
    (safe)            (RAI restored)       (ORR 61%)
+----------------------------------------------------------------+

Evidence Base — Key Literature

Limitations and Knowledge Gaps

1. BRAF V600E prognostic independence: While meta-analyses show significant associations with aggressive features, the independent prognostic value of BRAF V600E after multivariate adjustment remains debated. The borderline recurrence OR (1.56, 95% CI 1.00–2.41) underscores uncertainty (PMID: 41419184).

2. Overdiagnosis confounding: The substantial overdiagnosis of thyroid cancer (~25%) confounds epidemiological analyses and may inflate the apparent indolent behavior of BRAF-mutant PTMC in surveillance studies.

3. Redifferentiation durability: Phase II redifferentiation data (24-month PFS 68%) require longer follow-up and phase III confirmation. Optimal sequencing of redifferentiation vs. MKI therapy is undefined.

4. Resistance mechanisms: While three mechanisms have been identified (TAZ, FAO, RAS feedback), clinical strategies to overcome them remain largely preclinical. The interplay between multiple resistance pathways in individual patients is poorly understood.

5. Pediatric data gaps: Pediatric BRAF-mutant PTC has distinct biology (more aggressive despite excellent survival), but dedicated pediatric clinical trials for targeted therapies are lacking.

6. Single-cell resolution limitations: scRNA-seq studies have revealed immune trajectory and heterogeneity, but spatial transcriptomics data for BRAF-mutant PTC remain limited. Translating single-cell findings to clinical biomarkers requires validation.

7. Geographic and ethnic variation: BRAF V600E prevalence varies widely (40–80%), and GWAS susceptibility loci show population specificity (e.g., NRG1 in Korean, BATF/DHX35 in Italian populations). Cross-ethnic validation of molecular risk models is needed.

8. Active surveillance expansion: MAeSTro-EXP is extending AS to tumors up to 1.5 cm, but long-term outcomes for this expanded cohort are not yet available.

Proposed Follow-up Experiments/Actions

Near-Term (1–2 years)

1. Phase III redifferentiation trial: Prospective randomized trial comparing dabrafenib-trametinib redifferentiation + RAI vs. standard MKI therapy in BRAF V600E RAI-refractory DTC.

2. Combinatorial resistance studies: Clinical trials testing TAZ inhibitors or FAO inhibitors in combination with BRAF/MEK inhibitors in patients progressing on monotherapy.

3. ctDNA monitoring validation: Prospective study validating BRAF V600E ctDNA as a minimal residual disease biomarker after thyroidectomy, with sensitivity analysis against serum thyroglobulin.

4. Expanded active surveillance cohort: Long-term outcomes from MAeSTro-EXP (1.0–1.5 cm tumors) to define safe upper size limit for observation.

Medium-Term (2–5 years)

1. Immunotherapy biomarker discovery: Prospective correlation of PD-L1 expression, BRAF V600E status, and tumor immune microenvironment features with immunotherapy response in advanced DTC/ATC.

2. Multi-ethnic GWAS integration: Pan-ancestry GWAS combining existing data with African, South Asian, and Latin American cohorts to identify universal and population-specific PTC susceptibility loci.

3. Spatial multi-omics of dedifferentiation: Spatial transcriptomics and proteomics profiling of BRAF V600E PTC to PDTC to ATC transition specimens to map the molecular geography of dedifferentiation.

4. Organoid-guided personalized therapy: Clinical trial using patient-derived organoid drug sensitivity testing to guide second-line therapy selection in RAI-refractory DTC.

Long-Term (5+ years)

1. AI-integrated risk stratification: Development and validation of machine learning models integrating ultrasound features, molecular profiling, liquid biopsy, and clinical data for precision risk assessment.

2. Prevention trials: Interventional studies testing whether metabolic syndrome management (weight loss, NAFLD treatment) reduces PTC incidence or modifies BRAF V600E positivity rates.

Ontology Term Summary

Report generated from 5 investigation iterations, 17 confirmed findings, 182 papers reviewed. Last updated: 2026-05-05.